Gesynta Pharma
7 known investors
Gesynta Pharma develops pharmaceutical treatments for inflammation and pain by selectively inhibiting the enzyme mPGES-1. Its lead candidate vipoglanstat is in phase 2 clinical trials as a non-hormonal, non-opioid treatment for endometriosis, alongside a second candidate GS-073 for chronic inflammatory pain.
BiotechDigital HealthFemTech
Investors · 7
In the news
Frequently asked questions
- What does Gesynta Pharma do?
- Gesynta Pharma develops pharmaceutical treatments for inflammation and pain by selectively inhibiting the enzyme mPGES-1. Its lead candidate vipoglanstat is in phase 2 clinical trials as a non-hormonal, non-opioid treatment for endometriosis, alongside a second candidate GS-073 for chronic inflammatory pain.
- Who are Gesynta Pharma's investors?
- Gesynta Pharma's investors include Amboy Street Ventures, Catalyze Capital, Foreground Capital, Hadean Ventures, HealthCap, Industrifonden, XGEN Venture.